222 completed, 18 terminated, 15 unknown, 11 withdrawn. 271 Phase 2, 25 Phase 3, 19 Phase 1.
Follow Ribavirin: new trials by email Literature Review of Ribavirin trials Research Report on Ribavirin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment of CKD Patients With HCV SOF+DCV, OBV/PTV/r) ± ribavirin (RBV) - HCV Infection ( Genotype 4) in CKD Patients | Phase 2 / Phase 3 | Not yet recruiting | Tanta University | 50 | 2026-09-15 | 2026-08-20 |
| ISTH/ANRS 0409s INTEGRATE Lassa Fever Study Favipiravir, Ribavirin, Dexamethasone - Lassa Fever | Phase 2 / Phase 3 | Recruiting | Irrua Specialist Teaching Hospital | 1755 | 2025-05-02 | 2026-02-04 |
| Assessing Antiviral Treatments in Early Symptomatic RSV Ribavirin, Molnupiravir, Favipiravir - Respiratory Syncytial Virus, Respiratory Syncytial Virus, Human | Phase 2 | Recruiting | University of Oxford | 1000 | 2024-07-25 | 2025-07-02 |
| LAssa Fever Adjunct Treatment With DEXamethasone Dexamethasone, Ribavirin - Lassa Fever | Phase 2 | Recruiting | Bernhard Nocht Institute for Tropical Medicine | 42 | 2024-02-05 | 2025-02-06 |
| UMIT-1 Trial Favipiravir & Ribavirin for the Treatment of CCHF Favipiravir, Ribavirin - CCHF | Phase 1 / Phase 2 | Unknown | Liverpool School of Tropical Medicine | 24 | 2023-07-12 | 2023-10-05 |
| Treatment of Hemorrhagic Fever With Ribavirin Virazole - Hemorrhagic Fever | Phase 2 | Suspended | U.S. Army Medical Research and Development Command | 50 | 2022-10-31 | 2026-07-07 |
| Efficacy and Safety of Favipiravir and Ribavirin Formulation for Treatment of COVID-19 Ribavirin Capsules, Favipiravir - SARS-CoV2, COVID-19 | Phase 2 / Phase 3 | Unknown | The Scientific and Technological Research Council of Turkey | 100 | 2021-04-01 | 2021-04-02 |
| A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19 Nitazoxanide, Placebo Nitazoxanide, Ribavirin - SARS-CoV Infection, Covid19 | Phase 2 | Terminated | Rutgers, The State University of New Jersey | 7 | 2020-12-02 | 2022-05-05 |
| IFN Beta-1b and Ribavirin for Covid-19 Interferon beta-1b, Ribavirin - Covid19 | Phase 2 | Unknown | The University of Hong Kong | 96 | 2020-07-29 | 2020-07-31 |
| Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment Lopinavir/ritonavir, Ribavirin, Interferon Beta-1B - Novel Coronavirus Infection | Phase 2 | Completed | The University of Hong Kong | 127 | 2020-02-10 | 2020-04-15 |
| A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia Brequinar/Brequinar + Ribavirin - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | Clear Creek Bio, Inc. | 17 | 2018-12-20 | 2022-08-08 |
| The Diabetes Virus Detection and Intervention Trial Ribavirin + Pleconaril, Placebos - Type1 Diabetes Mellitus, Enterovirus | Phase 2 | Completed | Oslo University Hospital | 96 | 2018-08-30 | 2021-04-08 |
| Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects. Ravidasvir, Danoprevir, Ritonavir - HCV | Phase 2 / Phase 3 | Completed | Ascletis Pharmaceuticals Co., Ltd. | 425 | 2017-07-01 | 2020-07-28 |
| Ombitasvir /Paritaprevir/Ritonavir Plus Ribavirin on HCV GT4 OBV/PTV/r) ± ribavirin (RBV) - Hepatitis C Virus Infection | Phase 1 / Phase 2 | Completed | Beni-Suef University | 100 | 2017-01-05 | 2020-05-12 |
| Pembrolizumab (MK-3475) in Hepatocellular Carcinoma Elbasvir/Grazoprevir, Laboratory Biomarker Analysis, Pembrolizumab - BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 15 | 2016-12-09 | 2025-07-15 |
| Safety and Efficacy of Gratisovir (Sofosbuvir)- Ribavirin Therapy in Pediatric Patients Sofosbuvir Oral Product, Ribavirin - Pharmacological Action | Phase 2 / Phase 3 | Unknown | National Liver Institute, Egypt | 41 | 2016-12-01 | 2016-12-19 |
| Efficacy and Safety of Uprifosbuvir (MK-3682) + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041) Uprifosbuvir, Ruzasvir, Ribavirin - Hepatitis C | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 282 | 2016-11-16 | 2021-02-02 |
| A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection Faldaprevir, TD-6450, Ribavirin - Hepatitis C Viral Infection, Chronic Hepatitis C | Phase 2 | Completed | Trek Therapeutics, PBC | 25 | 2016-05-01 | 2017-10-17 |
| Sofosbuvir Plus Daclatasvir With or Without Ribavirin and Chronic HCV Genotype (GT) 4 (SOF and DCV), (SOF, DCV, and RBV) - Chronic Hepatitis C Virus Infection | Phase 2 / Phase 3 | Completed | Beni-Suef University | 946 | 2016-04-01 | 2020-05-15 |
| 12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF Ledipasvir/sofosbuvir, Ribavirin - HIV-1 Infection, Hepatitis C | Phase 2 | Terminated | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 7 | 2016-02-17 | 2018-05-02 |
Showing 20 of 271. Sign in to see all of them.
Hepatitis C (153) · Hepatitis C, Chronic (115) · HIV Infections (19) · Hepatitis (14) · Liver Diseases (8) · Bronchiolitis Obliterans Syndrome (4) · Hemorrhagic Fevers, Viral (4) · Leukemia, Myeloid, Acute (4) · COVID-19 (3) · Hepatitis, Chronic (3) · Infections (3) · Influenza, Human (3) · Lassa Fever (3) · Virus Diseases (3) · Anemia (2)
Merck Sharp & Dohme LLC (24) · Gilead Sciences (22) · Bristol-Myers Squibb (21) · Hoffmann-La Roche (18) · Vertex Pharmaceuticals Incorporated (14) · AbbVie (11) · National Institute of Allergy and Infectious Diseases (NIAID) (11) · AbbVie (prior sponsor, Abbott) (10) · ANRS, Emerging Infectious Diseases (9) · Boehringer Ingelheim (5) · Debiopharm International SA (4) · Jewish General Hospital (4) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (4) · U.S. Army Medical Research and Development Command (4) · Ascletis Pharmaceuticals Co., Ltd. (3)
United States (133) · France (55) · Puerto Rico (52) · Germany (49) · Canada (38) · Spain (27) · Australia (26) · United Kingdom (24) · Italy (21) · Belgium (17) · New Zealand (17) · Austria (16) · Poland (16) · Egypt (8) · Romania (7)
Robert H. Hyland, DPhil (5) · Daniel Cohen, MD (4) · Erin Castelloe, MD (3) · John McNally, PhD (3) · Raymond Chung, MD (3) · Sarit Assouline, MD (3)
PMID 24154738, PMID 24982088, PMID 25164700, PMID 25445400, PMID 26596948, PMID 26752189, PMID 28193518, PMID 28802814, PMID 28802816, PMID 30012435, PMID 30923816, PMID 30977945, PMID 31568620, PMID 15282352, PMID 15316341, PMID 15374882, PMID 15563253, PMID 15667486, PMID 15685543, PMID 15820563, PMID 15867490, PMID 16115185, PMID 16439867, PMID 16544259, PMID 16987047, PMID 17058240, PMID 17147494, PMID 17263626, PMID 17721093, PMID 18184077, PMID 18435468, PMID 18666223, PMID 19143532, PMID 19268724, PMID 19403902, PMID 19403903, PMID 19447518, PMID 19594300, PMID 19797971, PMID 19852040, PMID 19898214, PMID 20375406, PMID 20622678, PMID 20677940, PMID 20684729, PMID 20692693, PMID 20721883, PMID 20854821, PMID 20921898, PMID 21079746
2009 (8), 2014 (7), 2015 (7), 2008 (3), 2004 (1), 2005 (1), 2016 (1), 2023 (1), R01AI049141 (1), R01AI049508 (1), R01DA026727 (1), U01AI068636 (1), U01DK062444 (1), U01DK062467 (1), U01DK062483 (1)